CBX2 As a Therapeutic Target in Colorectal Cancer: Insights into the Altered Chromatin Accessibility via RUNX1-CBX2-MAP4K1 Axis

Gain and loss of function studies demonstrated that chromobox homolog 2 (CBX2) significantly promoted colorectal cancer (CRC) progression and chemoresistance in cell lines, patient-derived CRC organoids and xenografts.